Health Canada approves Rozlytrek® (entrectinib) for NTRK gene fusion-positive solid tumours in locally advanced or metastatic patients(1) By Araceli Richardson|2020-08-18T00:57:30-07:00April 28, 2020|
Erasca Raises $200 Million Series B Financing By Jonathan Lim, M.D.|2020-08-31T08:52:51-07:00April 27, 2020|
ORIC Pharmaceuticals Announces Pricing of Initial Public Offering By Araceli Richardson|2020-08-18T00:57:30-07:00April 23, 2020|
Chugai Obtains Approval for Additional Indication of Rozlytrek for ROS1 Fusion-Positive Non-Small Cell Lung Cancer By Araceli Richardson|2020-08-18T00:57:30-07:00February 21, 2020|
Black Diamond Therapeutics Announces Pricing of Initial Public Offering By Araceli Richardson|2020-08-18T00:57:30-07:00January 29, 2020|
